Break Boundaries.
Ignite Change.

Pioneering off-the-shelf dual-action therapeutic cancer vaccines with the goal of improving outcomes for people with melanoma and other tumor types.

First-in-Class Modulation of the Tumor Microenvironment

The dual mechanism of our T-win® cancer vaccines is designed to kill both tumor cells and immune-suppressive cells in the TME, by stimulating activation and expansion of T cells against IDO1+ and/or PD-L1+ cells. This results in the modulation of the TME, creates a more pro-inflammatory environment, and enhances anti-tumor activity via unleashing the tumor killing by effector T cells.

Considering participation in a clinical trial?